Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/30/20
End: 11/16/22
Due: 11/16/23
Phase: N/A
Priority: Normal
Start: 06/20/18
End: 07/25/19
Due: 07/25/20
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 12/31/14
Due: 12/31/15
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 02/28/17
Due: 02/28/18
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Bryostatin Treatment of Moderately Severe Alzheimer's Disease | NCT04538066 | Neurotrope Bioscience, Inc. | user2@example.com | None | 2020-08-30 | 2022-11-16 | 2023-11-16 | - | - | 2025-07-14 |
| A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine | NCT03560245 | Neurotrope Bioscience, Inc. | user2@example.com | None | 2018-06-20 | 2019-07-25 | 2020-07-25 | - | - | 2025-07-14 |
| Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease | NCT02221947 | Neurotrope Bioscience, Inc. | user2@example.com | None | 2014-06-30 | 2014-12-31 | 2015-12-31 | - | - | 2025-07-14 |
| A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease | NCT02431468 | Neurotrope Bioscience, Inc. | user2@example.com | None | 2015-11-30 | 2017-02-28 | 2018-02-28 | - | - | 2025-07-14 |